Hangzhou & San Diego, Oct 9, 2020 – Today, the In-vitro diagnostic manufacturer VivaChek announced the launch of two SARS-CoV-2 Ag tests for the fighting of global pandemic of COVID-19:
- VivaDiag™ SARS-Cov-2 Ag Rapid Test
- VivaDiag™ SARS-Cov-2 Ag FIA Test with VivaDiag™ POCT analyzer
Both tests are designed to detect the presence of the viral antigens of SARS-CoV-2 in nasal, nasopharyngeal or oropharyngeal swab specimens from suspected COVID-19 patients. They are intended to be used by healthcare professionals for the qualitative detection. Utilizing the lateral flow-based technology, VivaDiag™ SARS-CoV-2 Ag Rapid Test is easy to use and can generate results within 15 minutes, with no further requirement of any reading instrument. The antigen rapid test is extremely useful for the locations such as airport, train station, and convention center.
VivaDiag™ SARS-Cov-2 Ag FIA Test with VivaDiag™ POCT analyzer employ our advanced fluorescent immunoassay platform technology. Its capability of great analytic precision and high throughput (up to 120 tests per hour) makes it an indispensable tool for the screening, diagnosis and containing of COVID-19.
Neither of above two products is available for sale in the US yet, although VivaChek is seeking to obtain the Emergency Use Authorization (EUA) from USFDA.
Unfortunately, anyone is able to see the end of global pandemic and with the coming regular flu season, the mission to fight against the COVID-19 seems even more difficult. VivaChek is proud to invest all our know-hows and resources to develop VivaDiag™ SARS-CoV-2 FIA /Flu A/ Flu B Ag combo test, which will be launched in the coming weeks. It can be used for the simultaneous detection and differentiation of the antigens of SARS-CoV-2, influenza A and influenza B in the specimens from individuals suspected of respiratory viral infections. The test will serve as a powerful weapon for the healthcare professionals to contain the COVID-19 pandemic.
Exhibitor Data Sheet